Nasdaq-listed Trinity Biotech continued to generate solid sales growth, with sales in the third quarter up to $9.5 million (€10.6 million) from $7.6 million.

Operating profits were up by the same margin to $4.7 million, from $3.8 million.

But expenses more than doubled, mainly as a result of increased investment in sales and marketing in the US and Germany.